Dostarlimab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | PCDP1 |
| Clinical data | |
| Other names | TSR-042, WBP-285 |
| Drug class | Antineoplastic |
| ATC code | |
| Identifiers | |
| CAS Number | |
| PubChem SID | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6420H9832N1690O2014S44 |
| Molar mass | 144325.73 g·mol−1 |
Dostarlimab (TSR-042, WBP-285) (INN) is a monoclonal antibody designed for the treatment of cancer.[1][2]
Like several other available and experimental monoclonal antibodies, it is a PD-1 inhibitor. As of 2020[update], it is undergoing Phase I/II and Phase III clinical trials.[3][4][5] The manufacturer, Tesaro, announced prelimary successful results from the Phase I/II GARNET study.[3][6][7]
In 2020, the GARNET study announced that Dostarlimab was demonstrating potential to treat a subset of women with recurrent or advanced endometrial cancer.[8]
As of August 2020, Dostarlimab is not yet approved for any use, though license applications were filed with the FDA and EMA in early 2020.[9]
References
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Dostarlimab, American Medical Association.
- ^ World Health Organization (2018). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 119" (PDF). WHO Drug Information. 32 (2).
- ^ a b Clinical trial number NCT02715284 for "A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors (GARNET)" at ClinicalTrials.gov
- ^ Clinical trial number NCT03981796 for "A Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)" at ClinicalTrials.gov
- ^ Clinical trial number NCT03602859 for "A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST)" at ClinicalTrials.gov
- ^ "Data from GARNET study indicates robust activity of dostarlimab in patients with advanced or recurrent endometrial cancer". Tesaro (Press release). Retrieved 1 January 2020.
- ^ Scalea B (28 May 2019). "Dostarlimab Effective in Endometrial Cancer Regardless of MSI Status". Targeted Oncology. Retrieved 1 January 2020.
- ^ "GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer - Drugs.com MedNews". Drugs.com. Retrieved 29 April 2020.
- ^ "AnaptysBio Announces First Quarter 2020 Financial Results and Provides Pipeline Updates". GlobeNewsWire. 6 May 2020. Retrieved 17 August 2020.
External links
- "Dostarlimab". Drug Information Portal. U.S. National Library of Medicine.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |